The effects of vinblastine on the expression of human immunodeficiency virus type 1 long terminal repeat.
Previous work by our group has demonstrated induction of the HIV-LTR following exposure of cells to various DNA-damaging agents such as ultraviolet (UV) light, cisplatin, and doxorubicin. The current experiments were designed to determine the relative effects of the anti-mitotic drug vinblastine on expression of the HIV-LTR. Using human cervical carcinoma (HeLa) cells stably transfected with the chloramphenicol acetyl transferase (CAT) reporter transcriptionally driven by the HIV-LTR promoter, we demonstrated a 9-10-fold induction at 48-72 h following vinblastine treatment. Previous experiments had demonstrated repression of cisplatin or doxorubicin-mediated HIV induction by treatment with salicylic acid. The vinblastine induction also was repressed by salicylic acid treatment, but not by treatment with indomethacin, suggesting a role for the NF kappa B pathway in the inductive response. When UV exposure was coupled to the vinblastine treatment, there was no additive or synergistic effect evident, suggesting similar paths of induction between the two agents. Northern blots demonstrated that these agents were operating at the level of transcription and that salicylic acid inhibited vinblastine-mediated induction of HIV-LTR-CAT mRNA only if administered at the same time as vinblastine; addition of salicylic acid 2 h later had no effect on transcript accumulation. All combinations of treatments with vinblastine and/or salicylic acid markedly reduced cell survival.
Akan
E
E
University of Illinois Medical Center, Chicago, USA.
Chang-Liu
C M
CM
Watanabe
J
J
Ishizawa
K
K
Woloschak
G E
GE
D002470:Cell Survival / Q000187:drug effects; D015500:Chloramphenicol O-Acetyltransferase / Q000096:biosynthesis; D003513:Cycloheximide / Q000494:pharmacology; D017930:Genes, Reporter; D016325:HIV Long Terminal Repeat / Q000187:drug effects* / Q000528:radiation effects; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D006367:HeLa Cells; D006801:Humans; D016328:NF-kappa B / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis; D012459:Salicylates / Q000494:pharmacology; D020156:Salicylic Acid; D014158:Transcription, Genetic / Q000187:drug effects; D014162:Transfection; D014466:Ultraviolet Rays; D014747:Vinblastine / Q000494:pharmacology*
D016328:NF-kappa B; D011993:Recombinant Fusion Proteins; D012459:Salicylates; D014747:Vinblastine; D003513:Cycloheximide; D015500:Chloramphenicol O-Acetyltransferase; D020156:Salicylic Acid